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There is growing evidence linking vitamin D deficiency 
with risk of COVID-19. It is therefore distressing that there 
is major disagreement about the optimal serum level for 
25-hydroxyvitamin D (25(OH)D) and appropriate supplement 
dose. The UK Scientific Advisory Committee for Nutrition 
has set the lowest level for defining sufficiency (10 ng/ml or 
25 nmol/L) of any national advisory body or scientific society 
and consequently recommends supplementation with 10 
micrograms (400 IU) per day. We have searched for published 
evidence to support this but not found it. There is considerable 
evidence to support the higher level for sufficiency (20 ng/ml  
or 50 nmol/L) recommended by the European Food Safety 
Authority and the American Institute of Medicine and hence 
greater supplementation (20 micrograms or 800 IU per day). 
Serum 25(OH)D concentrations in the UK typically fall by 
around 50% through winter. We believe that governments 
should urgently recommend supplementation with 20–25 
micrograms (800–1,000 IU) per day.
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Vitamin D, COVID-19 and current guidance
Evidence for a possible impact of vitamin D deficiency on COVID-19 
has been strengthened recently by the positive Spanish trial of 
25-hydroxyvitamin D3 (25(OH)D3 or calcifediol) in hospitalised 
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patients1 and by the association between vitamin D deficiency and 
increased risk for COVID-19 seropositivity found in hospital staff 
from Birmingham, UK.2 There is a plausible scientific basis for this 
as 25(OH)D3 is a prohormone that can be metabolised to active, 
hormonal 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). When bound 
to its intracellular vitamin D receptor (VDR), 1,25(OH)2D3 is able to 
regulate many target genes, with beneficial effects on immune and 
lung cell function that may be compromised by vitamin D deficiency.3 
In the UK, serum 25(OH)D concentrations fall by about 50% from a 
peak in September to a trough in February (Fig 1).4 With much of the 
northern hemisphere experiencing a resurgence of the pandemic as 
we move into winter, it is increasingly urgent to ensure appropriate 
public health measures to prevent vitamin D deficiency.
There is unfortunately considerable variance between countries 
in recommendations for supplementation: 10 micrograms (400 IU) 
per day in the UK, 600 IU per day in the EU and 600 IU per day 
or 800 IU per day for those aged >70 years in the USA.5 The UK 
Scientific Advisory Committee on Nutrition (SACN) is an outlier 
among representative bodies in choosing the lowest blood level 
(25 nmol/L) of 25(OH)D to define sufficiency when compared with 
thresholds of 50 nmol/l set by the American Institute of Medicine 
(now National Academy of Medicine) and European Food Safety 
Authority, and 75 nmol/l set by the US Endocrine Society. The 
evidence base underlying the UK target serum level has been 
questioned by others,6 and we now explore it further.
Seeking the evidence base for the UK SACN threshold 
for vitamin D sufficiency at 25 nmol/L
SACN in their 2016 report7 state (p43, section 6.17): ‘In the UK, a 
serum 25(OH)D concentration <25 nmol/L has been the threshold 
adopted to define increased risk of rickets (DH, 1998).’ 
In turn, the DH (Department of Health) 1998 report8 states  
(p40 6.2.3): 
Plasma levels of 25(OH)vitamin D found in clinical rickets or 
osteomalacia range from undetectable to around 20nmo1/l 
[citing the 1991 DH report of the Panel on Dietary Reference 
Values of the Committee on Medical Aspects of Food Policy9] and 
a level of plasma 25(OH)vitamin D of 25nmo1/l has conventionally 
been used as a cut off for defining the lower limit of adequacy of 
vitamin D status [citing Grindulis et al 198610], although others 
have suggested slightly higher levels [citing Gloth et al 199511]. 
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The DH reports8,9 that underpin the SACN position do not 
stand close scrutiny. The 1991 DH report9 states (section 18.1.2): 
‘Plasma 25(OH)D concentrations in rickets range from not 
detectable to about 8 ng/ml’, citing Arnaud et al.12 However, 
this is definitely not what Arnaud et al reported: a case series of 
nine children with nutritional rickets, seven of whom had serum 
25(OH)D concentrations above 10 ng/ml (= 25 nmol/L) and up to 
approximately 50 nmol/L. 
Grindulis et al10 did indeed state: ‘For this study a vitamin D 
concentration <10 ng/ml (25 nmol/L) was taken to be suboptimal 
and <5 ng/ml deficient’ but no data were referenced in support of 
this statement.
Gloth et al11 state: ‘Reference ranges for our laboratory (normal 
range), 25 to 137 nmol/L (10 to 55 ng/mL)’. In the discussion of 
this paper, however they question the validity of the lower limit, 
commenting that: 
the elevation in intact PTH levels seen with 25-OHD serum levels 
between 25 and 37 nmol/L (10 and 15 ng/mL) is distressing if we 
define a vitamin deficiency as the Food and Nutrition Board does, 
ie, ‘that level of an essential nutrient that leads to an abnormal 
physiologic change.’ Since secondary hyperparathyroidism 
causes abnormal bone loss, among other physiological changes, 
then perhaps the lower limit of the normal range for serum  
25-OHD should be increased.
Here the trail ‘runs dry’ – seemingly the 25 nmol/L limit has 
been agreed by consensus within SACN rather than by referral 
to any specific source with the possible exception of the historic 
laboratory reference range (25 to 137 nmol/L) of the Johns 
Hopkins University School of Medicine, Baltimore as cited, but 
criticised, in Gloth et al.11
It is interesting that the earlier SACN (2007) position statement 
was much more circumspect and concluded (p38, section 13.118):
 Accumulating evidence suggests that vitamin D may be 
important for health outcomes other than rickets and 
osteomalacia, and that plasma concentrations of 25(OH)D 
several fold higher than 25 nmol/L may be required for optimal 
health.
It is unclear why subsequent SACN reports have not addressed 
this.
It seems then that the UK SACN definition of vitamin D 
deficiency as <25 nmol/L and consequently the 400 IU per day 
supplement dosing was based on consensus rather than on any 
systematic analysis of data. It may be more than a coincidence 
that 400 IU is approximately the amount of vitamin D in one 
teaspoon of cod liver oil, for over 70 years the standard daily 
supplement recommended in Norway. With the passage of time 
and subsequent reports from SACN this position seems to have 
become firmly entrenched without any further evidence to justify 
it.
The SACN/UK government advised dietary intake level of 400 IU  
per day for all >4 years was re-affirmed in June 202013 on the 
account that: 
This is the average daily amount of vitamin D (from natural 
food sources, fortified foods or supplements) needed by the 
majority (97.5%) of the population to maintain a serum 25(OH)
D concentration ≥25 nmol/L when UVB sunshine exposure is 
minimal.
The ‘97.5%’ is presumably based on the definition of reference 
nutrient intake (RNI) as used by DH (1998) – ‘two standard 
deviations above estimated average requirements’. In 1998 the 
Department of Health set no RNI for older children or for adults 
aged 18–64 but did set 400 IU (10 microgram) per day as the 
recommendation for adults ≥65.8 This report cited a randomised 
trial comparing no supplement with 400 IU per day and 800 IU  
per day completed through to 1 year in 109 institutionalised 
elderly people. This showed that serum 25(OH)D increased to  
>40 nmol/L in all subjects who received either 400 IU or 800 IU 
per day.14 This does not however address the greatly increased 
vitamin D supplement requirements needed to achieve sufficiency 
in people with obesity.15
Fig 1. Seasonal variation in serum vitamin D concentrations (mean (95% confidence interval)) among 7,437 white British (1958 British birth 
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The evidence base for 50 nmol/L as the threshold for 
25(OH)D sufficiency 
This has been reviewed elsewhere.5 The American Institute of 
Medicine (now called the National Academy of Medicine) and the 
European Food Safety Authority both set >50 nmol/L 25(OH)D as 
the definition for sufficiency while the US Endocrine Society sets a 
higher level of >75 nmol/L. Serum concentrations of parathyroid 
hormone rise with vitamin D deficiency but there is considerable 
variation between individuals. Evidence supporting 50 nmol/L as 
a recommended serum vitamin 25(OH)D level was strengthened 
by Malabanan et al16 who looked at the impact of vitamin D 
supplementation on parathyroid hormone levels in 35 people with 
different baseline levels of 25(OH)D. People with baseline serum 
25(OH)D concentrations in the ranges 27.5–39.9 and 40–49.9 
nmol/l showed significant falls in parathyroid hormone in response 
to vitamin D supplementation whereas people with baseline 
25(OH)D ≥50 nmol/l showed no significant fall in parathyroid 
hormone.
Muscle strength has also been studied as an outcome measure 
to define vitamin D sufficiency. Interestingly, the SACN (2016) 
report says (p68, section 6.169):
Evidence from cohort studies was also supportive of an 
association between mean serum 25(OH)D concentration and 
muscle strength and function when baseline serum 25(OH)D 
concentration is <50 nmol/L.7
Other studies have looked more broadly at associations between 
vitamin D status and all-cause mortality. Gaksch and colleagues17 
performed a meta-analysis across a European consortium of 
eight prospective studies including 26,916 study participants, 
median age 61.6 years, followed-up for median 10.5 years. 
Significant increases in all-cause mortality were seen with baseline 
serum 25(OH)D <50 nmol/L. There was no significant increased 
mortality risk at high levels up to 125 nmol/L, important since an 
earlier study had suggested a possible U-shaped dose response 
curve.18 
There is therefore a substantial body of evidence to support 
the 50 nmol/L definition of 25(OH)D sufficiency as set by the 
American Institute of Medicine and the European Food Safety 
Authority.
In the UK 55.4% of the population, rising to 69.3% in winter, 
are reported to have serum 25(OH)D <50 nmol/L and black, 
Asian, and minority ethnic populations, as well as people who by 
occupation or institutionalisation receive less sunlight exposure, 
are at still higher risk of insufficiency.19 A recent study of the UK 
Biobank cohort found that 92% of 6,433 UK-dwelling South Asians 
have 25(OH)D <50 nmol/L.20
Identification of the daily supplement dosage  
needed to achieve optimal vitamin D status defined 
as ≥50 nmol/L
Modelling based on a meta-analysis of 94 cohort studies that 
included 11,566 individuals supplemented for a median period of 
274 days suggests that for adults, supplementation with 800 IU  
per day (but not 400 IU per day) should be adequate, even in 
obese individuals, for achieving >50 nmol/L (Table 1).21 However, 
to achieve >75 nmol/L would typically require supplementation 
of between 3,000 IU per day to 4,000 IU per day for an obese 
individual. It seems reasonable to conclude from this meta-
analysis that a regular daily intake of at least 800 IU should be 
sufficient, even in obese individuals, to achieve a target blood 
level >50 nmol/L. A higher initial daily intake, eg 4,000 IU per day 
for the first 4 weeks, would be reasonable to achieve sufficiency 
quickly in people likely to be deficient during the current pandemic. 
Intermittent blood 25(OH)D monitoring and personalised 
replacement, although scientifically ideal, has a cost and is not 
essential given the safety of vitamin D supplementation at 
appropriate dosage.
Regarding safety, SACN (2016) concludes that: 
Upper limits for vitamin D recommended by EFSA, of 100 μg/d 
(4000 IU/d) for adults and children aged 11–17 y, 50 μg/d  
(2000 IU/d) for children aged 1–10 y, and 25 μg/d (1000 IU) 
for infants, are considered appropriate. The upper limits do not 
distinguish between total and supplementary vitamin D intake 
since dietary intakes of vitamin D make only a small contribution 
to total exposures at the ULs.7
Conclusion
The current UK SACN threshold for vitamin D sufficiency of  
25 nmol/L 25(OH)D is set too low and is not supported by evidence. 
A higher threshold of 50 nmol/L is supported by the evidence and is 
safely achievable by supplementation with at least 800 IU per day 
Table 1. Calculated daily vitamin D3 dose for achieving in vitamin D-deficient individuals target 
25-hydroxyvitamin D levels of 50 nmol/L and 75 nmol/L, respectively 
30-year-old person 70-year-old person
Target 25(OH)D level 50 nmol/L
50 kg body weight 9 micrograms (360 IU) 5 micrograms (200 IU)
75 kg body weight 13.5 micrograms (540 IU) 7.7 micrograms (308 IU)
100 kg body weight 18 micrograms (720 IU) 10 micrograms (400 IU)
Target 25(OH)D level 75 nmol/L
50 kg body weight 42 micrograms (1680 IU) 24 micrograms (960 IU)
75 kg body weight 63 micrograms (2520 IU) 36.5 micrograms (1460 IU)
100 kg body weight 84 micrograms (3360 IU) 49 micrograms (1960 IU)
Based on a systematic review of 94 cohort studies that included 11,566 supplemented individuals (Zittermann et al21). Baseline 25(OH)D level 25 nmol/L.
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(20 micrograms per day). Since vitamin D is widely sold in 1,000 
IU capsules, and it is universally agreed that doses up to 4,000 IU 
per day are safe, then a recommendation of 800–1,000 IU per 
day (20–25 micrograms per day) for all adults would be safe and 
sufficient and should be urgently promoted. ■
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